UBS Group
NEUP

UBS Group’s Neuphoria Therapeutics NEUP Stock Holding History

UBS Group’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.25K Sell
2,117
-199
-9% -$960 ﹤0.01% 8614
2026
Q1 		$9.43K Buy
2,316
+664
+40% +$2.81K ﹤0.01% 8441
2025
Q4 		$6.41K Sell
1,652
-516
-24% -$3.67K ﹤0.01% 8556
2025
Q3 		$25.6K Buy
+2,168
New +$20.1K ﹤0.01% 8004
2025
Q1 		– Sell
-2,978
Closed -$10.2K – 10930
2024
Q4 		$10.2K Buy
+2,978
New +$10.5K ﹤0.01% 8309
2024
Q3 		– Sell
-2,908
Closed -$26.8K – 10227
2024
Q2 		$26.8K Buy
2,908
+2,080
+251% +$22.7K ﹤0.01% 7121
2024
Q1 		$10.2K Buy
828
+801
+2,967% +$10.6K ﹤0.01% 7238
2023
Q4 		$487 Sell
27
-180
-87% -$5.14K ﹤0.01% 8638
2023
Q3 		$6.7K Buy
+207
New +$4.46K ﹤0.01% 7282
2023
Q1 		– Sell
-73
Closed -$4.05K – 10558
2022
Q4 		$4.05K Buy
73
+62
+564% +$5.38K ﹤0.01% 9397
2022
Q3 		$1K Buy
11
+6
+120% +$529 ﹤0.01% 10066
2022
Q2 		$0 Hold
5
– – ﹤0.01% 11072
2022
Q1 		$0 Sell
5
-81
-94% -$10.7K ﹤0.01% 11027
2021
Q4 		$13K Buy
+86
New +$13.2K ﹤0.01% 8480

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

UBS Group's NEUP Position: Q2 2026 in Review

UBS Group reduced its Neuphoria Therapeutics (NEUP) stake by 8.6% in Q2 2026, selling an estimated $960 and leaving 2,117 shares worth $9.25K. The position accounts for ﹤0.01% of the portfolio, ranked #8614.

UBS Group first reported a position in NEUP in Q4 2021 and has held it in 14 quarters since. The position peaked at $26.8K in Q2 2024. 22 funds tracked by Wall St. Rank hold NEUP as of Q2 2026.

  • UBS Group held 2,117 shares of Neuphoria Therapeutics worth $9.25K as of Q2 2026.
  • UBS Group sold 199 Neuphoria Therapeutics shares in Q2 2026, an estimated $960.
  • Neuphoria Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8614 holding.
  • UBS Group first reported a position in Neuphoria Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • UBS Group's Neuphoria Therapeutics position peaked at $26.8K in Q2 2024.
  • 22 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.